ArticleNature communications2023
Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Profiling of extracellular vesicles from primary hepatocytes, organoids, and mash patients identifies cell injury-specific signatures.Scientific reports · 2026Article
- Preliminary insights into gut microbiome shifts as screening proxy for MASLD disease progression.Scientific reports · 2026Article
- Molecular Imaging Probes for Early Detection and Staging of Liver Fibrosis.Chemical & biomedical imaging · 2025Review
- AI-Based Platelet-Independent Noninvasive Test for Liver Fibrosis in MASLD Patients.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials.JHEP reports : innovation in hepatology · 2025Article
- Metabolic dysfunction-associated steatotic liver disease in adults.Nature reviews. Disease primers · 2025Review
- Ionizable polymeric micelles (IPMs) for efficient siRNA delivery.Nature communications · 2025Article
- Article
- MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD.Hepatology international · 2024Review
- A FAPα-activated MRI nanoprobe for precise grading diagnosis of clinical liver fibrosis.Nature communications · 2024Article
- Shining a light on liver health: advancements in fluorescence-enhanced enzyme biosensors for early disease detection.Frontiers in bioengineering and biotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 15 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlike for advanced liver fibrosis, the practical rules for the early non-invasive diagnosis of cirrhosis in NAFLD remain not well defined. Here, we report the derivation and validation of a stepwise diagnostic algorithm in 1568 patients with NAFLD and liver biopsy coming from four independent cohorts. The study algorithm, using first the elastography-based tests Agile3+ and Agile4 and then the specialized blood tests FibroMeter
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.